Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "SEC"

2359 News Found

WHO prequalifies Syngenta’s innovative insecticide Sovrenta
News | April 23, 2025

WHO prequalifies Syngenta’s innovative insecticide Sovrenta

A new weapon in the global fight against malaria


Biocon Biologics secures market entry date for Yesafili in US
News | April 15, 2025

Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions


Nureca’s manufacturing subsidiary secures USFDA registration
News | April 14, 2025

Nureca’s manufacturing subsidiary secures USFDA registration

This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States


Fredun secures tender from TNMSC for supply of generic pharma products
News | April 14, 2025

Fredun secures tender from TNMSC for supply of generic pharma products

The supply of these goods is set to commence within the first quarter of FY26


OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru
Drug Approval | April 11, 2025

OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru

This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance


Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Drug Approval | April 09, 2025

Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s

Raichur site is the group’s largest API facility and part of a wider network of seven sites


Lyka Labs secures Indian patent for Pregabalin Gel 8%
News | April 08, 2025

Lyka Labs secures Indian patent for Pregabalin Gel 8%

Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain


AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Drug Approval | April 04, 2025

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone


Amcor's Bloom Biorenewables secures $14 million Series A Funding
Packaging | April 03, 2025

Amcor's Bloom Biorenewables secures $14 million Series A Funding

Bloom has pioneered a technology to transform plant waste into valuable chemical products


Morepen secures Loratadine approval for export to China
Drug Approval | April 01, 2025

Morepen secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets